Ann: Quarterly Activities and Cashflow Report, page-10

I think this has to do with going from mining to medical cannabis part of that deal with asx was they would hold decent cash reserves.

Also best to have cash that are funding ms research and production for T12 is ramping up and the roll out of Canntab eventually won't be cheap.

If they can get T12 to as round $1.5m revenue a quarter I think they can at least balance the books and bankroll roll out or MC products which should be the main money spinner eventually. Although hemp and other natural products can be a bit business in its own right, it's a volumes business with tight margins IMO.